From GlobeNewswire:

Pliant Therapeutics announced positive interim results from the INTEGRIS-PSC Phase 2a clinical trial of bexotegrast at 320 mg in patients with primary sclerosing cholangitis (PSC). The 320 mg dose group met its primary and secondary endpoints, demonstrating that bexotegrast was well tolerated over a 12-week period, with no severe or serious adverse events. Bexotegrast-treated patients also showed improvements in liver fibrosis markers and hepatocyte function. The company will host a webcast and conference call on February 5th to discuss the results. These findings support further study of bexotegrast in patients with PSC, where current therapies are limited.



Read more: Pliant Therapeutics Announces Positive Safety and